|Articles|August 9, 2021

What Will This Flu Season Look Like?

Author(s)Killian Meara

A conversation with William Schaffner, MD.

Last season, during the height of the COVID-19 pandemic, cases of influenza were essentially nonexistent.

Not surprisingly, the majority of experts, officials and physicians did not see that coming. Many were openly vocal about concerns of a possible “twindemic”, where the flu and COVID-19 would cause an even worse public health crisis.

There is not an exact explanation on why cases of the flu were so low, but the implementation of prevention measures such as masking and social distancing, combined with a lack of international travel, surely had something to do with it.

However, this coming flu season will see many less restrictions in place and world-wide travel begin again.

This leaves many wondering how this will impact the upcoming flu season.

Contagion recently sat down with William Schaffner, MD, medical director of the National Foundation for Infectious Diseases (NFID), to discuss what we might see in the coming months.

“I’m worried again that we’ll have a ‘twindemic’,” Schaffner said. “We’ll have COVID being transmitted, we’ll have flu being transmitted and I think we’ll be doing a lot of testing, to try and sort the two from each other as we take care of patients.”


Related to this article

REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.